Strong financial execution and …

Q: Can you provide an update about Cobenfy's sales performance that BMS started for the treatment of schizophrenia? A: Cobenfy, which was approved by the US FDA last year, started in the USA in the last quarter of 2024 by BMS in the United States. The turnover with the first quarter was around $ 27 million, which is about 48% above the average estimate of the analysts, which indicates a strong market traction. Bharatt Chowrira, CEO

Q: Could you explain the economic agreements with BMS and license houses in relation to Cobenfy? A: PureTech is entitled to a 3% license fee for sales with sales with license fees for $ 100 million and up to $ 400 million in sales milestones. In addition, PureTech receives a license fee of 2% for sales over 2 billion US dollars. There are also small milestones from BMS for development and sublicensing. Bharatt Chowrira, CEO

Q: What are the financial considerations for the phase 3 study with LYT-100 and why is external financing required? A: The phase 3 study for LYT-100 in IPF is expected to be a one-year, one-year treatment study, similar to earlier studies in this area, which is transferred significant funds on the current balance of PURETECH. Discussions will take place on potential financing mechanisms, including spinout, project financing and strategic partnerships. Bharatt Chowrira, CEO

Q: Can you submit an update via Seaporte therapy drugs and its financing status? A: SeaPort Therapeutics, now a private unit, promotes its LEAD program LYT-300 in the direction of a phase 2b study on a serious depressive disorder and initiates a phase 1 study for SPT-320 for generalized anxiety disorders. They are well capitalized after collecting $ 325 million in two risk customers. Bharatt Chowrira, CEO

Q: How does PureTech plan to solve the perceived value between his share price and the intrinsic value? A: PureTech examines various options to remedy the value circuit, including stock returns, offerings and potential private -equity discussions. The company continues to concentrate on the execution of its pipeline programs and evaluates the possibilities for the development of the shareholder value. Bharatt Chowrira, CEO

You can find the complete copy of the earnings call in the complete earnings call.

This article first appeared on Gurufocus.